What records are connected here?
- Evidence lanes
- 1
- Source years
- 2
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
In clinical trials1,3,4Evidence: Smaller human trialsMetabolic and weight
VK2735 is an experimental dual agonist of the GLP-1 and GIP receptors, studied for weight management.3 In the 13-week phase 2 VENTURE trial in adults with obesity or overweight, average weight loss was 9.1% to 14.7% depending on strength, compared with 1.7% on placebo; side effects were mainly gastrointestinal.3 No FDA approval is reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.3,4,6
| What it is | An investigational glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor dual agonist, according to the VENTURE trial report.3 |
|---|---|
| FDA status | Not FDA-approved. No FDA approval is reported in the sources reviewed here, and phase 3 trials are registered on ClinicalTrials.gov.1,3 |
| Human evidence | One published 13-week phase 2 randomized, double-blind, placebo-controlled trial in adults with obesity or overweight.3 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
VK2735 is an investigational drug that activates both the GLP-1 receptor and the GIP receptor, according to the 2026 VENTURE trial report.3
As a GLP-1/GIP receptor dual agonist, it is designed to activate both receptors. The VENTURE trial tested whether this reduces body weight.3
VENTURE randomly assigned adults with obesity, or overweight and at least one weight-related condition, and without diabetes, to one of several strengths of VK2735 or placebo for 13 weeks, between August 2023 and February 2024.3
Average weight loss was 9.1% to 14.7% with VK2735 and 1.7% with placebo. In the VK2735 groups, 130 of 140 participants lost at least 5% of their weight, compared with 4 of 34 on placebo.3
The most common side effects were gastrointestinal and became less frequent with continued use, according to the report.3
Evidence-strength label: Smaller controlled human trials. How this label is assigned
None of the sources reviewed here reports an approval of VK2735 by FDA.3,4
ClinicalTrials.gov lists a phase 3 trial of VK2735 for weight loss as recruiting in its November 16, 2026 record, and another phase 3 trial as active, not recruiting in its April 7, 2026 record.1,2
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list VK2735.4
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. VK2735 is not among them.5,6
Its effects and safety beyond 13 weeks and in larger groups of people, which the published phase 2 trial did not address.3
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for VK2735: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for VK2735 are a bounded selection, not every registration or paper about VK2735. For the years before VK2735 was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list VK2735 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name VK2735 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
In clinical trials; not FDA-approved. Published evidence is one 13-week phase 2 randomized trial. VK2735 is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
In clinical trials; not FDA-approved. Published evidence is one 13-week phase 2 randomized trial. VK2735 is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date November 16, 2026
ClinicalTrials.gov record NCT07868835↗Added to PeptideScanner November 16, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT07868835↗Source date November 16, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT07104383↗Source date April 7, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT07104500↗Source date November 24, 2025PeptideScanner currently has no selected PubMed literature metadata records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
6 of 6 selected trial records include at least one phase value; 6 of 6 include a status value in the retained structured contract.
0 of 0 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT05203237 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-02-17, and PeptideScanner's reviewed identity mapping was vk2735.
PeptideScanner retained ClinicalTrials.gov record NCT06068946 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-02-12, and PeptideScanner's reviewed identity mapping was vk2735.
PeptideScanner retained ClinicalTrials.gov record NCT06828055 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-10-06, and PeptideScanner's reviewed identity mapping was vk2735.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Selected records span February 12, 2025 to November 16, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07868835 at 2026-11-16T17:46:36.579Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was vk2735.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07104383 at 2026-11-16T17:46:36.579Z. Its registry update date was 2026-04-07, and PeptideScanner's reviewed identity mapping was vk2735.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07104500 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-11-24, and PeptideScanner's reviewed identity mapping was vk2735.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06828055 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-10-06, and PeptideScanner's reviewed identity mapping was vk2735.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05203237 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-02-17, and PeptideScanner's reviewed identity mapping was vk2735.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06068946 at 2026-11-16T17:46:36.579Z. Its registry update date was 2025-02-12, and PeptideScanner's reviewed identity mapping was vk2735.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
ClinicalTrials.gov · Official source · Source checked November 16, 2026
ClinicalTrials.gov · Official source · Source checked November 16, 2026
Obesity · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026